Pathological effects of signal peptide mutations have been characterized already in other genes (diseases) such as insulin (diabetes), COL10A1 (Schmid-type metaphyseal chondrodysplasia, MCDS), and COL5A1 (classical Ehlers–Danlos Syndrome, cEDS). This evidence concerns the gene COL10A1 and diabetes mellitus.